Stifel Downgrades Nivalis Therapeutics (NVLS) to Hold as Data Suggest No Meaningful Treatment Effect

November 29, 2016 6:19 AM EST
Get Alerts NVLS Hot Sheet
Price: $2.14 +1.42%

Rating Summary:
    1 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade NVLS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Stifel downgraded Nivalis Therapeutics (NASDAQ: NVLS) from Buy to Hold with a price target of $3.25 (from $16.00) after the company released Phase II data for cavosonstat in the treatment of patients with homozygous F508del CF that were stably on Orkambi. Based on the data released there was no treatment effect at 12 weeks for either the 200mg or 400mg dose of the drug as measured by either improvements in FEV1 or reductions in sweat chloride levels. There was an improvement in BMI in both groups that reached statistical significance in a pooled analysis along with transient improvements in sweat chloride levels.

Analyst Thomas Shrader commented, "These results were significantly less compelling than previous results in the SNO4 trial that treated a more difficult population (Exhibit 2). Based on today’s news we are basing our Nivalis price target on the expected cash at the end of 1Q17 – when the ongoing SNO7 trial is complete. We are lowering our rating to Hold."

For an analyst ratings summary and ratings history on Nivalis Therapeutics click here. For more ratings news on Nivalis Therapeutics click here.

Shares of Nivalis Therapeutics closed at $6.25 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Stifel

Add Your Comment